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Introduction
The identification of predictive factors of poor response
to methotrexate (MTX) in juvenile idiopathic arthritis
(JIA) patients could contribute to optimize the treatment
strategy, namely by the earlier introduction of biological
treatments.
Objectives
To identify baseline clinical or laboratorial predictive
factors of MTX poor response at 6 months in patients
with JIA.
Methods
In a cohort of 141 JIA patients registered in Reuma.pt
(the Portuguese Register of Rheumatic Diseases) we
selected patients diagnosed after 2000 and that were trea-
ted at least for 6 months with MTX (at least 10 mg/m2).
Univariate and multivariate logistic analyses were used to
identify the predictors for non-response to MTX treat-
ment during the first 6 months of treatment. Non-
response to MTX was defined according the American
College of Rheumatology pediatric 70 (ACR-ped 70) cri-
teria. Concomitant treatment with nsaids and corticoster-
oids up to 10 mg was allowed for all treatment groups.
For this analysis we included: sex, age, age at disease
onset, body surface, JIA subtype, disease duration, rheu-
matoid factor (RF), ANA, HLA-B27, uveitis, age at MTX
onset, MTX dosage, disease duration until the start of
MTX, baseline physician and patient/parents VAS, base-
line active and limited joints and ESR.
Results
From the 58 patients identified, 23 were excluded (2
started biological therapy before 6 months, 3 were on con-
comitant DMARD’s, 12 had insufficient data, 1 developed
criteria for systemic lupus erythematosus, 3 had inter-
rupted MTX and 2 were loss for follow-up). From our
population 43% have achieved ACR-ped 70 response and
the remaining 57% did not reach this response criterion.
The age at MTX onset (p = 0.03; responders 6.25 ± 5,
non-responders 9.67 ± 1.53) and body surface (p = 0.045;
responders 0.92 ± 0.36; non-responders 1.3 ± 0.26) were
predictors of ACR-ped 70 response. Gender, MTX dosage,
JIA subtype and the other covariates described above did
not interfere on patients’ response to MTX. We studied
the association of the 2 significant predictors (age at MTX
onset and body surface) with response in a multivariate
model, but they behave as collinear variables, loosing sig-
nificance by increasing the standard error. Thus we kept
in the model age at MTX onset adjusted to the potential
confounders gender, JIA subtype and disease duration
until start MTX. Age at MTX onset has remained an inde-
pendent significant predictor of ACR response (p = 0.037,
OR 0.777).
Conclusion
MTX response was not dependent on subtype, gender and
dosage. Older age at MTX onset was correlated with
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